IAN MORTIMER - 10 Mar 2022 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
PRESIDENT & CEO, Director
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
10 Mar 2022
Net transactions value
$0
Form type
4
Filing time
14 Mar 2022, 16:15:42 UTC
Previous filing
03 Jun 2021
Next filing
14 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Award $0 +400,000 $0.000000 400,000 10 Mar 2022 Common Shares 400,000 $30.01 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.